Patamostat mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414793

CAS#: 114568-32-0 (mesylate)

Description: Patamostat mesylate, a guanidinobenzoate, is a trypsin inhibitor which is being developed by Eisai for the treatment of acute pancreatitis.

Chemical Structure

img
Patamostat mesylate
CAS# 114568-32-0 (mesylate)
Instruction

Theoretical Analysis

MedKoo Cat#: 414793
Name: Patamostat mesylate
CAS#: 114568-32-0 (mesylate)
Chemical Formula: C21H24N4O7S2
Exact Mass: 0.00
Molecular Weight: 508.560
Elemental Analysis: C, 49.60; H, 4.76; N, 11.02; O, 22.02; S, 12.61

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 114568-32-0 (mesylate); 114568-26-2 (free base)  

Synonym: Patamostat mesylate; E3123; E-3123; E 3123

IUPAC/Chemical Name: Benzoic acid, 4-((aminoiminomethyl)amino)-, 4-((2-(2,5-dioxo-1-pyrrolidinyl)ethyl)thio)phenyl ester, monomethanesulfonate

InChi Key: HTSFLDCSCNSKJW-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H20N4O4S.CH4O3S/c21-20(22)23-14-3-1-13(2-4-14)19(27)28-15-5-7-16(8-6-15)29-12-11-24-17(25)9-10-18(24)26;1-5(2,3)4/h1-8H,9-12H2,(H4,21,22,23);1H3,(H,2,3,4)

SMILES Code: O=C(OC1=CC=C(SCCN2C(CCC2=O)=O)C=C1)C3=CC=C(NC(N)=N)C=C3.CS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 508.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Iwatsuki K, Horiuchi A, Yonekura H, Ren LM, Chiba S. E-3123, a new synthetic protease inhibitor, protects against deoxycholic acid-induced acute pancreatitis in dogs. Arch Int Pharmacodyn Ther. 1990 Nov-Dec;308:168-77. PMID: 1711836.

2: Satake K, Ha SS, Hiura A, Nishiwaki H. The therapeutic effect of a new synthetic protease inhibitor (E-3123) on hemodynamic changes during experimental acute pancreatitis in dogs. Gastroenterol Jpn. 1993 Feb;28(1):64-71. doi: 10.1007/BF02775005. PMID: 8440425.

3: Miyamoto K, Hishinuma I, Nagakawa J, Nagaoka N, Yamanaka T, Wakabayashi T. [Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis]. Nihon Yakurigaku Zasshi. 1988 May;91(5):285-93. Japanese. doi: 10.1254/fpj.91.285. PMID: 3410375.

4: Kazama M, Kobayashi K, Tahara C, Miyajima Y, Endo Y, Tanaka H, Nakatani T, Tajimi K. [Improving effect of the synthetic protease inhibitor E-3123 on experimental DIC in dogs]. Nihon Yakurigaku Zasshi. 1992 Jul;100(1):47-58. Japanese. doi: 10.1254/fpj.100.47. PMID: 1644370.

5: Hirano T, Manabe T, Ohshio G, Nio Y. Improved survival in mice with diet- induced pancreatitis treated with new potent protease inhibitor, E-3123 and a broad spectrum antibiotic, cefmetazole. Nihon Geka Hokan. 1992 May 1;61(3):213-23. PMID: 1444701.

6: Hirano T, Manabe T. A new synthetic protease inhibitor, E-3123, prevents lysosomal and mitochondrial fragility in rat caerulein-induced pancreatitis. J Int Med Res. 1992 Jun;20(3):211-7. doi: 10.1177/030006059202000302. PMID: 1383065.

7: Hirano T, Manabe T. Effect of short-term pancreatico-biliary duct obstruction with intraductal hypertension on subcellular organelle fragility and pancreatic adenylate energy metabolism in rats: protective effect of a new protease inhibitor, E-3123. Acta Chir Belg. 1994 Mar-Apr;94(2):80-5. PMID: 7517090.

8: Hirano T, Manabe T, Yotsumoto F, Ohshio G, Nio Y. Effect of short-termed pancreatico-biliary duct obstruction on lysosomal enzyme in rats: protective effect of a potent new protease inhibitor, E-3123. Nihon Geka Hokan. 1992 May 1;61(3):234-48. PMID: 1280076.

9: Nishiwaki H, Ko I, Hiura A, Ha SS, Satake K, Sowa M. Renal microcirculation in experimental acute pancreatitis of dogs. Ren Fail. 1993;15(1):27-31. doi: 10.3109/08860229309065568. PMID: 8441833.

10: Hirano T, Manabe T, Imanishi K, Yotsumoto F, Kyogoku T, Tobe T. A new synthetic protease inhibitor, E-3123, reduces organelle fragility of acinar cells in rat caerulein pancreatitis. Nihon Geka Hokan. 1991 Nov 1;60(6):406-14. PMID: 1820013.